Omniscope commences groundbreaking medical diagnostics research in Malta
Summary
Scientific Co-founder, Dr. Holger Heyn, renowned scientist and Team Leader at the National Centre for Genomic Analysis (CNAG-CRG) said that: “Our desire is for our cutting-edge technology to be of service to the global community in these challenging times of heightened emerging pandemic risks. We aim to apply science to rapidly bring solutions we so urgently need right now.” Dr. Heyn highlighted that Omniscope’s first product seeks to become a universal diagnostic tool that listens to the immune system to broadly detect disease at the earliest stages through simple, minimally invasive clinical tests. Our immediate action is to bring MiRXES’ Covid-19 solutions and other RNA technologies to the people of Malta.” “The dynamics of today’s biotech industry make a compelling case for international investors, especially when it’s founded by world-class scientists and industry experts - all these combined with Omniscope’s aim to bring healthcare to everyone, everywhere, is what makes this endeavor truly special”, highlights Lynnette Ang, Omniscope’s Co-founder and People and Sustainability Officer, who has a background in asset management. Co-founders and longtime friends and collaborators, Dr. Holger Heyn, Vijay Vaswani, Dr. Lihan Zhou, and Lynnette Ang, came together in the face of a global pandemic to find ways to meaningfully contribute to the scientific response to this threshold moment. It represents a breakthrough in the detection and understanding of disease, one that we believe will lead to interceptive rather than curative medicine, saving countless lives which today are lost to systemic inefficiencies and diagnostics limitations.